Journal of Diabetes (Apr 2024)

Association of obstructive sleep apnea symptoms with all‐cause mortality and cause‐specific mortality in adults with or without diabetes: A cohort study based on the NHANES

  • Qian Zhang,
  • Qi Zhang,
  • Xiaomin Li,
  • Gang Du,
  • Xiaojin Feng,
  • Runtao Ding,
  • Yuhua Chi,
  • Yongping Liu

DOI
https://doi.org/10.1111/1753-0407.13538
Journal volume & issue
Vol. 16, no. 4
pp. n/a – n/a

Abstract

Read online

Abstract Background The association between obstructive sleep apnea syndrome (OSAS) and mortality has not been extensively researched among individuals with varying diabetic status. This study aimed to compare the relationship of OSAS with all‐cause and cause‐specific mortality in US individuals with or without diabetes based on data from the National Health and Nutrition Examination Survey (NHANES). Methods The study included participants from the NHANES 2005–2008 and 2015–2018 cycles with follow‐up information. OSAS data (OSAS.MAP10) was estimated from the questionnaire. Hazard ratios (HRs) and the 95% confidence interval (CI) of OSAS for mortality were calculated by Cox regression analysis in populations with different diabetes status. The relationships between OSAS and mortality risk were examined using survival curves and restricted cubic spline curves. Results A total of 13 761 participants with 7.68 ± 0.042 follow‐up years were included. In the nondiabetic group, OSAS.MAP10 was positively associated with all‐cause, cardiovascular, and cancer mortality. In individuals with prediabetes, OSAS.MAP10 was positively related to all‐cause mortality (HR 1.11 [95% CI: 1.03–1.20]) and cardiovascular mortality (HR 1.17 [95% CI: 1.03–1.33]). The relationship between OSAS.MAP10 and the risk of all‐cause mortality and cancer mortality exhibited L‐shaped curves in diabetes patients (both with nonlinear p values <.01). Further threshold effect analysis revealed that OSAS was positively related to death risk when OSAS.MAP10 exceeded the threshold scores. Conclusion The relationship between OSAS and mortality differed among participants with or without diabetes. Individualized clinical treatment plans should be developed in clinical practice to reduce the risk of death for patients with different metabolic conditions.

Keywords